Nykode Therapeutics ASA Capital Reinvestment Ratio
Nykode Therapeutics ASA capital reinvestment ratio. Nykode Therapeutics ASA (NYKD) has a Capital Reinvestment Ratio of 0.15x as of March 2022, meaning it reinvests 0% of its operating cash flow (Nkr96.14 Million) in capital expenditures (Nkr14.06 Million). Check Nykode Therapeutics ASA (NYKD) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Nykode Therapeutics ASA (2020–2021)
Capital reinvestment ratio of Nykode Therapeutics ASA from 2020 to 2021. This chart tracks Nykode Therapeutics ASA's Capital Reinvestment Ratio across 2 annual periods. Also explore Nykode Therapeutics ASA (NYKD) net asset momentum to track the company's year-over-year net asset growth rate.
Nykode Therapeutics ASA Capital Reinvestment Ratio by Year (2020–2021)
Nykode Therapeutics ASA capital reinvestment ratio by year from 2020 to 2021. For the full cash flow conversion analysis, see NYKD cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (NOK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.75x | Nkr1.16 Million | Nkr871.00K | ▲ +137214.0% |
| 2020 | 0.00x | Nkr180.27 Million | Nkr99.00K | — |